Fig. 6: LAM IgM monoclonal antibody drives superior Mtb restriction in human whole blood.
a, Macrophage restriction assay. Each treatment (50 µg ml−1 antibody; 1 µg ml−1 rifampin) was added to human MDMs infected with Mtb-276, a luciferase reporter strain for Mtb in the H37Rv genetic background. Growth curves in the presence of each antibody treatment were generated by taking luminescence readings every 24 h up to 96 h. The y axis (Mtb survival) is the area under the Mtb growth curve normalized by the no-antibody condition of each donor. Each point is the triplicate average from one donor. Each donor is represented by a unique marker shape. Error bars denote the mean with standard deviation. Repeated-measures one-way ANOVA with Sidak’s multiple-comparisons test was performed. P values of relevant comparisons are shown. b, Whole-blood restriction assay. Each antibody (25 µg ml−1) was tested for its ability to drive Mtb restriction in the context of fresh human whole blood using Mtb-276. The y axis (Mtb survival) is the area under the Mtb growth curve, normalized by the no-antibody condition of each donor. Growth curves were generated by taking luminescence readings every 24 h up to 120 h. Each point is the triplicate average from one donor. Error bars denote the mean with standard deviation. Ordinary one-way ANOVA with Sidak’s multiple-comparisons test was performed. P values of relevant comparisons are shown.
